复方丹参注射液联合伊马替尼治疗急性淋巴细胞白血病临床研究

Clinical Study on Compound Danshen Injection Combined with Imatinib for Acute Lymphoblastic Leukemia

目的:观察复方丹参注射液联合伊马替尼对急性淋巴细胞白血病患者造血及免疫功能的影响。方法:选择70例急性淋巴细胞白血病患者为研究对象,按随机数字表法分为对照组和观察组各35例。对照组给予化疗+伊马替尼治疗,观察组在对照组基础上给予复方丹参注射液治疗。比较2组临床疗效,检测治疗前后血白细胞(WBC)、红细胞(RBC)、血小板(BPC)计数和血红蛋白(Hb)水平的变化,检测外周血T淋巴细胞亚群(CD3^(+),CD4^(+),CD8^(+)及CD4^(+)/CD8^(+))水平的变化。结果:治疗前,2组外周血WBC、RBC、BPC计数及Hb水平比较,差异无统计学意义(P>0.05)。治疗后,2组外周血RBC、BPC计数及Hb水平较治疗前上升,WBC计数较治疗前下降(P<0.05);且观察组WBC、RBC及Hb高于对照组(P<0.05)。治疗前,2组CD3^(+)、CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+)水平比较,差异无统计学意义(P>0.05)。治疗后,2组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平较治疗前降低(P<0.05),但是观察组降低程度小于对照组(P<0.05)。结论:复方丹参注射液联合伊马替尼治疗急性淋巴细胞白血病具有较好的疗效,可以有效改善患者骨髓造血功能和免疫功能。

Objective:To observe the effect of compound Danshen injection combined with imatinib on hematopoiesis and immune function of patients with acute lymphoblastic leukemia.Methods:A total of 70 cases of patients with acute lymphoblastic leukemia were selected as study objects,and were divided into the control group and the observation group according to the random number table method,with 35 cases in each group.The control group was treated with chemotherapy and imatinib,and the observation group was additionally treated with compound Danshen injection based on the treatment of the control group.The clinical effects in the two groups were compared;the changes in the levels of white blood cell(WBC),red blood cell(RBC),blood platelet count(BPC)and hemoglobin(Hb)before and after treatment were detected;the changes in the levels of T lymphocyte subsets including CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in peripheral blood were detected.Results:Before treatment,there was no significant difference being found in the comparison of the counts of WBC,RBC,BPC and the Hb levels between the two groups(P>0.05).After treatment,the counts of RBC and BPC and the Hb levels in peripheral blood in the two groups were increased when compared with those before treatment,and WBC counts were decreased(P<0.05);WBC,RBC and Hb in the observation group were higher than those in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)between the two groups(P>0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were decreased when compared with those before treatment(P<0.05),but the decrease in the observation group was less significant than that in the control group(P<0.05).Conclusion:The therapy of compound Danshen injection combined with imatinib has a good curative in the treatment of acute lymphoblastic leukemia,which can effectively improve bone marrow hematopoietic function and immune function of patients.